Abstract
Liquid crystalline nanoparticles (LCNPs) are lipid self-assembled nanostructures that meet plenty of advantageous features. The commonly used substrates for LCNPs preparation are glyceryl monooleate. The impact of other LCNPs forming substrates like Plurol® has not been extensively explored. Galantamine (GAL) is used as a typical therapy to control the symptoms of Alzheimer's disease (AD). The existing study intends to study Plurol® as an emerging cart for the conveyance of GAL to the brain after nasal application. Different stabilizers; Poloxamer 407, Myri 53 and Myrj 59 have been studied along with different water content in order to select the best formula that can permeate both the nasal mucosa and the BBB. In vitro and in vivo examinations had been performed to test for the applicability of the fabricated formulae. Results revealed the successful encapsulation of GAL into the developed Plurol-based cubosomes. The optimized formula had a particle size of 205 ± 4.38 nm, PDI of 0.356 ± 0.016, zeta potential of 2.44 ± 0.947 and entrapment efficiency of 60.8%. Y-maze task results showed that GAL LCNPs treated resulted in 39% boost in percentage alternation relative to the Streptozotocin (STZ) group. In addition, results of Morris water maze task showed that mice received GAL cubosomal gel settled longer in the target quadrant (time increased by 34.67 s relative to that recorded for the STZ group). The ex vivo and in vivo results point to the better performance of the cubic gel in terms of enhanced permeation through nasal mucosa and reversed STZ-induced cognitive impairment compared to the cubosomal dispersion.
[Display omitted]